Abstract
Emphysematous cystitis is a rare, severe infection of the urinary bladder caused by gas-forming organisms like Escherichia coli and Klebsiella pneumoniae (K. pneumoniae). Common risk factors are female sex, chronic urinary infection, immunosuppression, diabetes mellitus, and neurogenic bladder. We report a case of K. pneumoniae emphysematous cystitis in a diabetic male patient being treated with empagliflozin. With this case report, we aim to highlight the potential role of an SGLT-2 inhibitor such as empagliflozin in developing severe urinary infections such as emphysematous cystitis.